A-Raf Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several tyrosine protein kinases (VEGFR and PDGFR) and Raf kinases. It inhibits A-Raf by disrupting the MAPK/ERK signaling pathway, which is vital for cell division and proliferation. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $138.00 $255.00 $273.00 $403.00 $12240.00 | 6 | |
Dabrafenib selectively inhibits the activity of BRAF kinases. While it is specific to BRAF, it can indirectly impact A-Raf by modulating the overall RAF/MEK/ERK signaling pathway, essential for cell growth and differentiation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib, primarily targeting BRAF V600E mutations, can also affect A-Raf indirectly. It modulates the RAF/MEK/ERK signaling cascade, leading to reduced cell proliferation in certain cancer cells. | ||||||
AZ628 | 878739-06-1 | sc-364418 | 5 mg | $230.00 | 3 | |
AZ628 is a RAF inhibitor that targets CRAF and BRAF, and indirectly A-Raf. By inhibiting these kinases, it disrupts the MAPK/ERK signaling pathway, impacting cell growth and proliferation. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a potent inhibitor of c-Raf, which can indirectly affect A-Raf activity. By inhibiting c-Raf, it impacts the RAF/MEK/ERK signaling cascade, crucial for cell signaling and proliferation. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $363.00 | 5 | |
SCH772984 is an ERK inhibitor that indirectly influences A-Raf activity by inhibiting downstream components of the MAPK/ERK pathway, leading to altered cell signaling and growth. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib, a MEK inhibitor, indirectly influences A-Raf activity. It targets MEK1 and MEK2, affecting the downstream signaling of the RAF/MEK/ERK pathway, and thereby modulating cell proliferation and apoptosis. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, another MEK inhibitor, indirectly affects A-Raf. It targets the downstream components of the MAPK/ERK pathway, impacting cell growth and differentiation processes influenced by A-Raf. | ||||||
LY3009120 | 1454682-72-4 | sc-507538 | 5 mg | $125.00 | ||
LY3009120 targets pan-RAF kinases, potentially affecting A-Raf. It inhibits RAF isoforms and their dimerization, impacting the MAPK/ERK signaling pathway and cellular responses controlled by A-Raf. | ||||||